Pharmala Biotech Executes Definitive Agreement To Form Special Purpose Vehicle, Restora Neurosciences, For Clinical Development Of Patented Novel Mdxx Molecule Apa-01
May 13 (Reuters) - Pharmala Biotech Holdings Inc MDMA.CD:
PHARMALA BIOTECH EXECUTES DEFINITIVE AGREEMENT TO FORM SPECIAL PURPOSE VEHICLE, RESTORA NEUROSCIENCES, FOR CLINICAL DEVELOPMENT OF PATENTED NOVEL MDXX MOLECULE APA-01
PHARMALA BIOTECH HOLDINGS INC - CO AND ALUVARIS TO EACH HOLD 50% OF RESTORA NEUROSCIENCES SPV
PHARMALA BIOTECH HOLDINGS INC - RESTORA TO PAY PHARMALA $500,000 ONE-TIME LICENSE FEE UPON FUNDING THRESHOLD
PHARMALA BIOTECH HOLDINGS INC - LICENSE BECOMES FINAL WHEN RESTORA RAISES AT LEAST $2.5 MILLION IN CASH SUBSCRIPTIONS
PHARMALA BIOTECH HOLDINGS INC - TO GRANT RESTORA EXCLUSIVE WORLDWIDE ROYALTY-BEARING LICENSE FOR APA-01
PHARMALA BIOTECH HOLDINGS INC - TO RECEIVE 3% PERPETUAL ROYALTY ON NET SALES OF LICENSED PRODUCTS
Recommended Articles












Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.